Humana Inc. (NYSE:HUM) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC lowered its stake in shares of Humana Inc. (NYSE:HUM) by 3.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 22,207 shares of the insurance provider’s stock after selling 838 shares during the quarter. Yousif Capital Management LLC’s holdings in Humana were worth $10,167,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in HUM. Exchange Traded Concepts LLC lifted its position in shares of Humana by 103.0% during the third quarter. Exchange Traded Concepts LLC now owns 2,883 shares of the insurance provider’s stock worth $1,403,000 after purchasing an additional 1,463 shares during the last quarter. Caprock Group LLC grew its position in shares of Humana by 3.6% during the 3rd quarter. Caprock Group LLC now owns 1,421 shares of the insurance provider’s stock valued at $693,000 after buying an additional 50 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Humana by 2.8% during the third quarter. UMB Bank n.a. now owns 805 shares of the insurance provider’s stock valued at $392,000 after purchasing an additional 22 shares during the period. Czech National Bank raised its stake in shares of Humana by 46.4% during the 3rd quarter. Czech National Bank now owns 21,656 shares of the insurance provider’s stock worth $10,536,000 after purchasing an additional 6,866 shares in the last quarter. Finally, Aaron Wealth Advisors LLC bought a new stake in shares of Humana during the third quarter valued at approximately $213,000. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of HUM traded down $12.00 during trading hours on Wednesday, hitting $315.98. 3,340,465 shares of the company were exchanged, compared to its average volume of 1,998,779. The firm’s fifty day moving average is $329.86 and its 200 day moving average is $398.38. Humana Inc. has a fifty-two week low of $299.23 and a fifty-two week high of $541.21. The company has a market cap of $38.12 billion, a price-to-earnings ratio of 15.64, a P/E/G ratio of 1.91 and a beta of 0.45. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.63.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a net margin of 2.34% and a return on equity of 19.44%. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same period in the prior year, the firm posted $9.38 EPS. The company’s quarterly revenue was up 10.7% on a year-over-year basis. On average, equities analysts anticipate that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s payout ratio is currently 17.86%.

Insider Buying and Selling at Humana

In other news, Director Jorge S. Mesquita purchased 545 shares of the stock in a transaction dated Tuesday, February 20th. The shares were purchased at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.29% of the company’s stock.

Analysts Set New Price Targets

HUM has been the subject of a number of analyst reports. UBS Group reaffirmed a “neutral” rating and set a $370.00 price objective (down from $530.00) on shares of Humana in a report on Friday, January 26th. Barclays dropped their target price on Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a report on Tuesday, April 2nd. Mizuho lowered their price objective on shares of Humana from $550.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, January 26th. Raymond James initiated coverage on Humana in a report on Friday, March 22nd. They set a “market perform” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft downgraded Humana from a “buy” rating to a “hold” rating and lowered their price target for the stock from $595.00 to $360.00 in a report on Thursday, January 25th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average price target of $454.63.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.